900174-64-3

Basic information

• Product Name: 4-BroMo-2-ethoxy-1-fluorobenzene
• Synonyms: 4-BroMo-2-ethoxy-1-fluorobenzene;Benzene, 4-bromo-2-ethoxy-1-fluoro-;2-fluoro-5-bromophenyl ether
• CAS NO: 900174-64-3
• Molecular Formula: C₈H₈BrFO
• Molecular Weight: 219.0509232
• Mol File: 900174-64-3.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-BroMo-2-ethoxy-1-fluorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BroMo-2-ethoxy-1-fluorobenzene(900174-64-3)
• EPA Substance Registry System: 4-BroMo-2-ethoxy-1-fluorobenzene(900174-64-3)

Safety Data

• Hazardous Substances Data: 900174-64-3(Hazardous Substances Data)

Usage

General Description

4-Bromo-2-ethoxy-1-fluorobenzene is a chemical compound with the molecular formula C8H8BrFO. It is a derivative of benzene with a bromine atom, an ethoxy group, and a fluorine atom attached to the aromatic ring. 4-BroMo-2-ethoxy-1-fluorobenzene is used in the synthesis of various pharmaceuticals and agrochemicals. It is also employed in the production of organic materials and as an intermediate in the manufacturing of other fine chemicals. Due to its functional groups, 4-Bromo-2-ethoxy-1-fluorobenzene is a versatile building block in organic chemistry and can be used in a variety of reactions to create diverse compounds with potentially valuable properties.

Upstream product

• 74-96-4 ethyl bromide 
• 112204-58-7 5-Bromo-2-fluorophenol 

Downstream Products

• 1062614-64-5 1-(difluoromethoxy)-4-((3-ethoxy-4-fluorophenyl)ethynyl)-2-methylbenzene 
• 900174-65-4 3-ethoxy-4-fluorophenylboronic acid 
• 445019-49-8 N-(3-ethoxy-4-fluorobenzoyl)-D-serine methyl ester 
• 445026-29-9 3-ethoxy-4-fluorobenzoic acid 

Relevant articles and documents

Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC

Deacetylation of uridyldiphospho-3-O-(R-hydroxydecanoyl)-N-acetylglucosamine by LpxC is the first committed step in the Pseudomonas aeruginosa biosynthetic pathway to lipid A; homologous enzymes are found widely among Gram-negative bacteria. As an essential enzyme for which no inhibitors have yet been reported, the P. aeruginosa LpxC represents a highly attractive target for a novel antibacterial drug. We synthesized several focused small-molecule libraries, each composed of a variable aromatic ring, one of four heterocyclic/spacer moieties, and a hydroxamic acid and evaluated the LpxC inhibition of these compounds against purified P. aeruginosa enzyme. To ensure that the in vitro assay would be as physiologically relevant as possible, we synthesized a tritiated form of the specific P. aeruginosa glycolipid substrate and measured directly the enzymatically released acetate. Several of our novel compounds, predominantly those having fluorinated substituents on the aromatic ring and an oxazoline as the heterocyclic moiety, demonstrated in vitro IC50 values less than 1 μM. We now report the synthesis and in vitro evaluation of these P. aeruginosa LpxC inhibitors.